4 results on '"*NEUROLOGISTS"'
Search Results
2. Neurological disorders associated with COVID-19 in Sri Lanka.
- Author
-
Chang, Thashi, Wijeyekoon, Ruwani, Keshavaraj, Ajantha, Ranawaka, Udaya, Senanayake, Sunethra, Ratnayake, Pyara, Senanayake, Bimsara, Caldera, Manjula C., Pathirana, Gamini, Sirisena, Darshana, Wanigasinghe, Jithangi, Gunatilake, Saman, Keshavaraj, A., Ranawaka, U. K., Senanayake, S., Ratnayake, P., Senanayake, B., Caldera, M. C., Halahakoon, D., and Wijesekara, D. S.
- Subjects
NEUROLOGICAL disorders ,GUILLAIN-Barre syndrome ,NEUROLOGIC manifestations of general diseases ,SARS-CoV-2 Omicron variant ,COVID-19 ,EPILEPSY ,MELAS syndrome - Abstract
Background: Neurological manifestations of SARS-CoV-2 infection have been reported from many countries around the world, including the South Asian region. This surveillance study aimed to describe the spectrum of neurological disorders associated with COVID-19 in Sri Lanka. Methods: COVID-19 patients manifesting neurological disorders one week prior and up to six weeks after infection were recruited from all the neurology centres of the government hospitals in Sri Lanka from May 2021 – May 2022. Data was collected using a structured data form that was electronically transmitted to a central repository. All patients were evaluated and managed by a neurologist. Data were analysed using simple descriptive analysis to characterise demographic and disease related variables, and simple comparisons and logistic regression were performed to analyse outcomes and their associations. Results: One hundred and eighty-four patients with neurological manifestations associated with COVID-19 were recruited from all nine provinces in Sri Lanka. Ischaemic stroke (31%) was the commonest neurological manifestation followed by encephalopathy (13.6%), Guillain–Barre syndrome (GBS) (9.2%) and encephalitis (7.6%). Ischaemic stroke, encephalitis and encephalopathy presented within 6 days of onset of COVID-19 symptoms, whereas GBS and myelitis presented up to 10 days post onset while epilepsy and Bell palsy presented up to 20 – 40 days post onset. Haemorrhagic stroke presented either just prior to or at onset, or 10 – 25 days post onset of COVID-19 symptomatic infection. An increased frequency of children presenting with encephalitis and encephalopathy was observed during the Omicron variant predominant period. A poor outcome (no recovery or death) was associated with supplemental oxygen requirement during admission (Odds Ratio: 12.94; p = 0.046). Conclusions: The spectrum and frequencies of COVID-19 associated neurological disorders in Sri Lanka were similar to that reported from other countries, with strokes and encephalopathy being the commonest. Requiring supplemental oxygen during hospitalisation was associated with a poor outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper
- Author
-
Rakusa, Martin, Öztürk, Serefnur, Moro, Elena, Helbok, Raimund, Bassetti, Claudio L, Beghi, Ettore, Bereczki, Daniel, Bodini, Benedetta, Di Liberto, Giovanni, Jenkins, Thomas M, Macerollo, Antonella, Maia, Luis F, Martinelli-Boneschi, Filippo, Pisani, Antonio, Priori, Alberto, Sauerbier, Anna, Soffietti, Riccardo, Taba, Pille, von Oertzen, Tim J, Zedde, Marialuisa, Crean, Michael, Burlica, Anja, Cavallieri, Francesco, and Sellner, Johann
- Subjects
advocacy ,COVID-19 Vaccines ,SARS-CoV-2 ,neurological disorders ,Vaccination ,COVID-19 ,610 Medicine & health ,infectious disease prevention ,vaccination ,vaccine skepticism ,Humans ,Pandemics ,Nervous System Diseases ,Vaccination Hesitancy ,Post-Acute COVID-19 Syndrome ,Neurology ,Settore MED/26 - Neurologia ,Neurology (clinical) ,610 Medizin und Gesundheit - Abstract
BACKGROUND Health risks associated with SARS-CoV-2 infection are undisputed. Moreover, the capability of vaccination to prevent symptomatic, severe and fatal COVID-19 is recognized. There is also early evidence that vaccination can reduce the chance for long COVID-19. Nonetheless, the willingness to get vaccinated and receive booster shots remains subpar among people with neurologic disorders. Vaccine scepticism not only jeopardizes collective efforts to end the COVID-19 pandemic but puts individual lives at risk as some chronic neurologic diseases are associated with a higher risk for an unfavorable COVID-19 course. AIM In this position paper, the NeuroCOVID-19 Task Force of the European Academy of Neurology (EAN) summarizes the current knowledge on the prognosis of COVID-19 among patients with neurologic disease, elucidates potential barriers to vaccination coverage and formulates strategies to overcome vaccination hesitancy. A survey among the task force members on the phenomenon of vaccination hesitancy among people with neurologic disease supports the lines of argumentation. RESULTS The study revealed that people with multiple sclerosis and other nervous system autoimmune disorders are most skeptical of SARS-CoV-2 vaccination. The prevailing concerns included the chance of worsening the pre-existing neurological condition, vaccination-related adverse events, and drug interaction. RECOMMENDATIONS The EAN NeuroCOVID-19 task force reinforces the key role of neurologists as advocates of COVID-19 vaccination. Neurologists need to argue in the interest of their patients about the overwhelming individual and global benefits of COVID-19 vaccination. Moreover, they need to keep on eye on this vulnerable patient group, their concerns and the emergence of potential safety signals.
- Published
- 2022
4. Immunotherapies in pediatric neurology during the COVID-19 pandemic: A pragmatic approach.
- Author
-
Reddy, Chaithanya, Bhagwat, Chandana, and Saini, Arushi
- Subjects
IMMUNOGLOBULIN analysis ,CYTOKINES ,COVID-19 ,NEUROLOGY ,COMPLEMENT (Immunology) ,NEUROLOGICAL disorders ,INFLAMMATION ,IMMUNOMODULATORS ,RISK assessment ,IMMUNOTHERAPY ,CHILDREN - Abstract
Immunotherapy is an important treatment modality for several pediatric neurology conditions. The immunosuppressive therapies may predispose to a heightened risk of infection and fatal consequences. The paper aims to examine the immunological effects of various commonly used immunomodulators and their associated risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection. Immunotherapies may exhibit different effects at the different stages of coronavirus disease 19 (COVID-19) pathogenesis. Conventional immunosuppressive therapies appear to produce less favorable results or may aggravate the risk of infection, especially during the primary response phase. Whereas immunomodulators such as inhibitors of pro-inflammatory cytokines, antagonists of complement activity, and those drugs which decrease viral-neutralizing antibodies levels seem to have beneficial effects during the secondary hyper inflammation phase of infection. However, adequate clinical data is yet to be available for most of the immunotherapies. Based on the emerging evidence, the authors attempt to draw some conclusions of practical importance on the applications of different immunomodulators for children with pediatric neurological disorders in the COVID-19 pandemic. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.